(Q35540910)

8 August 2017

1 reference

title

Nocturnal symptom complex in PD and its management (English)

1 reference

8 August 2017

1

K Ray Chaudhuri

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

8 August 2017

23 September 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14504376

full work available at URL

13 March 2024

https://www.neurology.org/doi/full/10.1212/WNL.61.6_suppl_3.S17

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

13 March 2024

1 reference

8 August 2017

61

1 reference

8 August 2017

6 Suppl 3

1 reference

8 August 2017

S17-23

1 reference

Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD.

8 August 2017

2

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Acta Neurologica Scandinavica

13 March 2024

3

87

167

1993

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Head tremor after a remission of spasmodic torticollis

13 March 2024

4

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine

13 March 2024

5

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect?

13 March 2024

6

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Parkinson's disease and sleepiness: an integral part of PD.

13 March 2024

7

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Variation of visual evoked potential delay to stimulation of central, nasal, and temporal regions of the macula in optic neuritis

13 March 2024

9

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Nigrostriatal collaterals to thalamus degenerate in parkinsonian animal models

13 March 2024

10

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease

13 March 2024

11

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

The pedunculopontine nucleus: its role in the genesis of movement disorders

13 March 2024

12

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Contributions of the pedunculopontine region to normal and altered REM sleep.

13 March 2024

13

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Hypocretin (orexin) deficiency in human narcolepsy.

13 March 2024

15

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

CSF hypocretin/orexin levels in narcolepsy and other neurological conditions.

13 March 2024

16

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale

13 March 2024

17

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Daytime sleepiness and other sleep disorders in Parkinson's disease

13 March 2024

18

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease

13 March 2024

19

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Sleep in patients with Parkinson's disease and normal subjects prior to and following levodopa administration

13 March 2024

21

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder.

13 March 2024

22

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease.

13 March 2024

23

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases

13 March 2024

24

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness

13 March 2024

25

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study

13 March 2024

30

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls.

13 March 2024

31

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

13 March 2024

Restless legs syndrome

33

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease

13 March 2024

34

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Acta Neurologica Scandinavica

13 March 2024

39

100

163

1999

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Improvement of sleep architecture in PD with subthalamic nucleus stimulation.

13 March 2024

40

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Clozapine in the treatment of psychosis in Parkinson's disease

13 March 2024

42

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

The emerging role of clozapine in the treatment of movement disorders

13 March 2024

43

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Modafinil treatment of pramipexole-associated somnolence

13 March 2024

44

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

13 March 2024

49

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset

13 March 2024

51

1 reference

https://api.crossref.org/works/10.1212/WNL.61.6_SUPPL_3.S17

13 March 2024

Identifiers

1 reference

8 August 2017

1 reference